切換：
- 簡略
- 詳細(MARC)
- ISBD
-
Messenger RNA therapeutics /
紀錄類型 ： 書目-語言資料,印刷品: 單行本
其他作者 ： Jurga, Stefan,
出版項 ： Cham :Springer,[2022]
面頁冊數 ： 1 online resource (xii, 446 pages) :illustrations (chiefly color).
內容註 ： Intro -- Introduction: IVT Messenger RNA in the Syringe -- Contents -- Roadmap to the Development of mRNA Therapeutics: From Molecule Design and Delivery Strategies to Manufacturing, Quality Control, and Regulatory Considerations -- 1 Introduction -- 2 mRNA Design Strategies -- 2.1 Reducing mRNA Immunogenicity -- 2.2 Optimizing Protein Expression -- 2.3 Optimizing mRNA Stability -- 3 Delivery Strategies for mRNA Therapeutics -- 3.1 Lipid Nanoparticles for mRNA Delivery -- 3.2 Other Materials for mRNA Delivery -- 3.3 mRNA Drug Product Route of Administration
內容註 ： 4 Manufacturing of mRNA Drug Products -- 4.1 mRNA Drug Substance Manufacturing -- 4.2 mRNA Drug Product Manufacturing -- 5 Quality Control of mRNA Therapeutics -- 5.1 Drug Substance (mRNA) CQAs and Quality Control Strategy -- 5.2 Drug Product (mRNA-LNPs) CQAs and Quality Control Strategy -- 6 Conclusion and Future Directions -- References -- Messenger RNA for Prophylaxis -- 1 Introduction -- 2 mRNA Vaccines: Categories and Biological Function -- 3 Advances in mRNA Constructs -- 3.1 5' Capping -- 3.2 Untranslated Regions (UTRs) -- 3.3 Poly(A)-Tail
內容註 ： 3.4 Nucleotide Modification and Codon Optimization -- 3.5 Purity -- 3.6 Self-Amplifying Specific Features -- 4 mRNA Carrier Technologies -- 4.1 Tropism and Uptake Efficiency -- 4.2 The Art of Endosomal Escape -- 4.3 Formulation -- 4.4 Stability -- 5 Conclusions -- References -- Messenger RNA Therapeutics: Start of a New Era in Medicine -- 1 Introduction -- 2 Production of IVT mRNA -- 3 Immunogenicity of IVT mRNA -- 4 Strategies to Increase the Stability and Reduce the Immunogenicity of IVT mRNA -- 4.1 Capping (m7GpppN or m7Gp3N) -- 4.2 Tailing -- 4.3 Untranslated Regions (UTRs)
內容註 ： 4.4 Coding Region -- 5 Purification of Synthetic mRNA -- 6 Synthetic mRNA Platforms and their Features -- 6.1 Unmodified mRNA -- 6.2 Modified mRNA -- 6.3 Sequence-Optimized Unmodified mRNA -- 6.4 Replicon RNA -- 7 In Vivo Delivery Strategies of Exogenous mRNA -- 7.1 Delivery of Naked mRNA -- 7.2 Cationic Liposome-Mediated or Cationic Nanoemulsion (CNE)-based RNA Transfection -- 7.3 Peptide-based Delivery -- 7.4 Electroporation and Nucleoporation -- 7.5 Gene Gun-Mediated Delivery of mRNA -- 7.6 Use of Polymer Nanomaterials -- 7.7 Virus-like Replicon Particle (VRP)-based Delivery of mRNA
內容註 ： 7.8 Other Lesser-Known Methods -- 8 Applications of mRNA Therapeutics -- 8.1 mRNA as a Therapeutic Agent for Replacement of Defective Protein within the Cell -- 8.2 mRNA as Vaccines Against Cancer -- 8.3 Dendritic Cell (DC) Vaccines -- 8.4 mRNA Vaccines in Prevention of Diseases -- 8.5 mRNA-Mediated Genome Editing -- 8.6 Generation of Induced Pluripotent Stem Cells (iPSCs) using mRNA -- 9 Safety of mRNA Therapeutics -- 9.1 The Safety Concern Over the Use of Non-Natural Nucleotides/Nucleosides in IVT mRNA -- 9.2 Safety Considerations Regarding the Encoded Protein -- 10 Conclusions -- References
標題 ： Chemotherapy. -
標題 ： mRNA vaccines. -
標題 ： Messenger RNA. -
ISBN ： 9783031084157
ISBN ： 3031084152
LEADER 04394nam 2200445 i 4500
001 52163
003 NhCcYBP
005 20240425154801.8
006 m o d
007 cr cnu|||unuuu
008 220925s2022 sz a o 000 0 eng d
020 $a9783031084157$q(electronic bk.)
020 $a3031084152$q(electronic bk.)
020 $z9783031084140
020 $z3031084144
024 7 $a10.1007/978-3-031-08415-7$2doi
035 $aebs3389720
040 $aNhCcYBP$cNhCcYBP
041 $aeng
050 4$aRM263$b.M47 2022
072 7$aMFN$2bicssc
072 7$aMED107000$2bisacsh
072 7$aMFN$2thema
082 04$a615.5/8$223/eng/20221004
245 00$aMessenger RNA therapeutics /$cStefan Jurga, Jan Barciszewski, editors.
264 1$aCham :$bSpringer,$c[2022]
264 4$c�2022
300 $a1 online resource (xii, 446 pages) :$billustrations (chiefly color).
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
490 1 $aRNA technologies ;$vvolume 13
505 0 $aIntro -- Introduction: IVT Messenger RNA in the Syringe -- Contents -- Roadmap to the Development of mRNA Therapeutics: From Molecule Design and Delivery Strategies to Manufacturing, Quality Control, and Regulatory Considerations -- 1 Introduction -- 2 mRNA Design Strategies -- 2.1 Reducing mRNA Immunogenicity -- 2.2 Optimizing Protein Expression -- 2.3 Optimizing mRNA Stability -- 3 Delivery Strategies for mRNA Therapeutics -- 3.1 Lipid Nanoparticles for mRNA Delivery -- 3.2 Other Materials for mRNA Delivery -- 3.3 mRNA Drug Product Route of Administration
505 8 $a4 Manufacturing of mRNA Drug Products -- 4.1 mRNA Drug Substance Manufacturing -- 4.2 mRNA Drug Product Manufacturing -- 5 Quality Control of mRNA Therapeutics -- 5.1 Drug Substance (mRNA) CQAs and Quality Control Strategy -- 5.2 Drug Product (mRNA-LNPs) CQAs and Quality Control Strategy -- 6 Conclusion and Future Directions -- References -- Messenger RNA for Prophylaxis -- 1 Introduction -- 2 mRNA Vaccines: Categories and Biological Function -- 3 Advances in mRNA Constructs -- 3.1 5' Capping -- 3.2 Untranslated Regions (UTRs) -- 3.3 Poly(A)-Tail
505 8 $a3.4 Nucleotide Modification and Codon Optimization -- 3.5 Purity -- 3.6 Self-Amplifying Specific Features -- 4 mRNA Carrier Technologies -- 4.1 Tropism and Uptake Efficiency -- 4.2 The Art of Endosomal Escape -- 4.3 Formulation -- 4.4 Stability -- 5 Conclusions -- References -- Messenger RNA Therapeutics: Start of a New Era in Medicine -- 1 Introduction -- 2 Production of IVT mRNA -- 3 Immunogenicity of IVT mRNA -- 4 Strategies to Increase the Stability and Reduce the Immunogenicity of IVT mRNA -- 4.1 Capping (m7GpppN or m7Gp3N) -- 4.2 Tailing -- 4.3 Untranslated Regions (UTRs)
505 8 $a4.4 Coding Region -- 5 Purification of Synthetic mRNA -- 6 Synthetic mRNA Platforms and their Features -- 6.1 Unmodified mRNA -- 6.2 Modified mRNA -- 6.3 Sequence-Optimized Unmodified mRNA -- 6.4 Replicon RNA -- 7 In Vivo Delivery Strategies of Exogenous mRNA -- 7.1 Delivery of Naked mRNA -- 7.2 Cationic Liposome-Mediated or Cationic Nanoemulsion (CNE)-based RNA Transfection -- 7.3 Peptide-based Delivery -- 7.4 Electroporation and Nucleoporation -- 7.5 Gene Gun-Mediated Delivery of mRNA -- 7.6 Use of Polymer Nanomaterials -- 7.7 Virus-like Replicon Particle (VRP)-based Delivery of mRNA
505 8 $a7.8 Other Lesser-Known Methods -- 8 Applications of mRNA Therapeutics -- 8.1 mRNA as a Therapeutic Agent for Replacement of Defective Protein within the Cell -- 8.2 mRNA as Vaccines Against Cancer -- 8.3 Dendritic Cell (DC) Vaccines -- 8.4 mRNA Vaccines in Prevention of Diseases -- 8.5 mRNA-Mediated Genome Editing -- 8.6 Generation of Induced Pluripotent Stem Cells (iPSCs) using mRNA -- 9 Safety of mRNA Therapeutics -- 9.1 The Safety Concern Over the Use of Non-Natural Nucleotides/Nucleosides in IVT mRNA -- 9.2 Safety Considerations Regarding the Encoded Protein -- 10 Conclusions -- References
533 $aElectronic reproduction.$bIpswich, MA$nAvailable via World Wide Web.
588 0 $aOnline resource; title from PDF title page (SpringerLink, viewed October 4, 2022).
650 0$aChemotherapy.$327503
650 0$amRNA vaccines.$3100982
650 0$aMessenger RNA.$398626
700 1 $aJurga, Stefan,$eeditor.$1https://isni.org/isni/0000000071964270$3100983
700 1 $aBarciszewski, Jan,$eeditor.$1https://isni.org/isni/0000000081568570$3100984
710 2 $aEBSCOhost$387894
776 08$iPrint version:$z3031084144$z9783031084140
830 0$aRNA technologies ;$vv. 13.$3100981
856 40$uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3389720$zClick to View (限總院院內)
Messenger RNA therapeutics /Stefan Jurga, Jan Barciszewski, editors. - 1 online resource (xii, 446 pages) :illustrations (chiefly color). - RNA technologies ;volume 13. - RNA technologies ;v. 13..
Intro -- Introduction: IVT Messenger RNA in the Syringe -- Contents -- Roadmap to the Development of mRNA Therapeutics: From Molecule Design and Delivery Strategies to Manufacturing, Quality Control, and Regulatory Considerations -- 1 Introduction -- 2 mRNA Design Strategies -- 2.1 Reducing mRNA Immunogenicity -- 2.2 Optimizing Protein Expression -- 2.3 Optimizing mRNA Stability -- 3 Delivery Strategies for mRNA Therapeutics -- 3.1 Lipid Nanoparticles for mRNA Delivery -- 3.2 Other Materials for mRNA Delivery -- 3.3 mRNA Drug Product Route of Administration
Electronic reproduction.
Ipswich, MA
Available via World Wide Web.
ISBN: 9783031084157
Standard No.: 10.1007/978-3-031-08415-7doiSubjects--Topical Terms:
27503
Chemotherapy.
LC Class. No.: RM263 / .M47 2022
Dewey Class. No.: 615.5/8
Intro -- Introduction: IVT Messenger RNA in the Syringe -- Contents -- Roadmap to the Development of mRNA Therapeutics: From Molecule Design and Delivery Strategies to Manufacturing, Quality Control, and Regulatory Considerations -- 1 Introduction -- 2 mRNA Design Strategies -- 2.1 Reducing mRNA Immunogenicity -- 2.2 Optimizing Protein Expression -- 2.3 Optimizing mRNA Stability -- 3 Delivery Strategies for mRNA Therapeutics -- 3.1 Lipid Nanoparticles for mRNA Delivery -- 3.2 Other Materials for mRNA Delivery -- 3.3 mRNA Drug Product Route of Administration
Electronic reproduction.
Ipswich, MA
Available via World Wide Web.
ISBN: 9783031084157
Standard No.: 10.1007/978-3-031-08415-7doiSubjects--Topical Terms:
27503
Chemotherapy.
LC Class. No.: RM263 / .M47 2022
Dewey Class. No.: 615.5/8
- 館藏(0)
- 心得(0)
- 標籤
- 相同喜好的讀者(0)
- 相關資料(0)
發表心得